Asset Details
Do you wish to reserve the book?
Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?
Do you wish to request the book?
Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?
2023
Overview
Background
Gd levels are higher in tissues of animals with compromised renal function, but studies to compare levels after exposure to different macrocyclic gadolinium-based contrast agents (GBCAs) are lacking. We compared Gd levels in tissues of subtotally nephrectomised (SN) rats after repeated exposure to macrocyclic GBCAs.
Methods
Sprague–Dawley SN male rats (19 per group) received 16 injections of gadoteridol, gadobutrol, or gadoterate meglumine at 0.6 mmol Gd/kg 4 times/weeks over 4 weeks. A control group of healthy male rats (
n
= 10) received gadoteridol at the same dosage. Plasma urea and creatinine levels were monitored. Blood, cerebrum, cerebellum, liver, femur, kidney(s), skin and peripheral nerves were harvested for Gd determination by inductively coupled plasma-mass spectrometry at 28 and 56 days after the end of treatment.
Results
Plasma urea and creatinine levels were roughly twofold higher in SN rats than in healthy rats at all timepoints. At day 28, Gd levels in the peripheral nerves of gadobutrol- or gadoterate-treated SN animals were 5.4 or 7.2 times higher than in gadoteridol-treated animals (
p
< 0.001). Higher Gd levels after administration of gadobutrol or gadoterate
versus
gadoteridol were also determined in kidneys (
p
≤ 0.002), cerebrum (
p
≤ 0.001), cerebellum (
p
≤ 0.003), skin (
p
≥ 0.244), liver (
p
≥ 0.053), and femur (
p
≥ 0.271). At day 56, lower Gd levels were determined both in SN and healthy rats for all GBCAs and tissues, except the femur.
Conclusions
Gd tissue levels were lower following gadoteridol exposure than following gadobutrol or gadoterate exposure.
